Gilead Sciences Share News

Morningstar published 10 Best Value Stocks to Buy for the Long Term, undervalued blue-chip stocks with low price to fair value. Valuation and future return of each stock analyzed, compared to the S&P 500, Bristol-Myers has the highest potential rate of return. In comparison to Morningstar's 10 Best Value Stocks with 10 Best Dividend Stocks, Bristol-Myers stands out as undervalued with a high po...

AbbVie is a Dividend King poised for growth. Gilead Sciences is a stable, low-risk candidate for investors.

Gilead Sciences reported positive Phase 3 data for lenacapavir, a biannual HIV PrEP therapy, leading to a 12% stock boost. Q1 earnings showed growth in HIV product sales, with Trodelvy's notable 39% increase, and total revenue beating estimates by $350 million. Financially, Gilead has a current ratio of just over one, indicating the ability to meet short-term obligations, despite high leverage ...

Income-oriented investors love finding dividend stocks to buy now. That's particularly true when those stocks are on sale, as many continue to be.

Gilead Sciences reports positive Phase III trial results for lenacapavir, showing zero incident cases of HIV infection in the treatment group. Results suggest the potential for lenacapavir to revolutionize HIV prevention and treatment, leading to market expansion and creating shareholder value. Gilead's diversified revenue streams from HIV, liver disease, COVID-19, and oncology products positio...

Support for Gilead shares sits near 57.

Gilead Sciences NASDAQ: GILD saw its stock jump nearly 10% yesterday after announcing groundbreaking results from its HIV treatment trial. The biopharmaceutical company revealed 100% efficacy in its Phase 3 HIV prevention trial, marking the first trial showing zero infections.

One method of identifying which stocks to buy is to find those with price-to-earnings (P/E) ratios below their industry peers or historical averages. A low P/E suggests the stock possesses underlying worth that is not fully reflected in its current price.